Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Two-dose ChAdOx1 nCoV-19 vaccine protection against COVID-19 hospital admissions and deaths over time: a retrospective, population-based cohort study in Scotland and Brazil

Open access
Katikireddi, Srinivasa Vittal, Cerqueira-Silva, Thiago, Vasileiou, Eleftheria, Robertson, Chris, Amele, Sarah, Pan, Jiafeng, Taylor, Bob, Boaventura, Viviane, Werneck, Guilherme Loureiro, Flores-Ortiz, Renzo, Agrawal, Utkarsh, Docherty, Annemarie B, McCowan, Colin, McMenamin, Jim, Moore, Emily, Ritchie, Lewis D, Rudan, Igor, Shah, Syed Ahmar, Shi, Ting, Simpson, Colin R, Barreto, Mauricio L, Oliveira, Vinicius de Araujo, Barral-Netto, Manoel, Sheikh, Aziz · 2022 · The Lancet

Abstract

BACKGROUND: Reports suggest that COVID-19 vaccine effectiveness is decreasing, but whether this reflects waning or new SARS-CoV-2 variants-especially delta (B.1.617.2)-is unclear. We investigated the association between time since two doses of ChAdOx1 nCoV-19 vaccine and risk of severe COVID-19 outcomes in Scotland (where delta was dominant), with comparative analyses in Brazil (where delta was uncommon). METHODS: In this retrospective, population-based cohort study in Brazil and Scotland, we linked national databases from the EAVE II study in Scotland; and the COVID-19 Vaccination Campaign, Acute Respiratory Infection Suspected Cases, and Severe Acute Respiratory Infection/Illness datasets in Brazil) for vaccination, laboratory testing, clinical, and mortality data. We defined cohorts of adults (aged ≥18 years) who received two doses of ChAdOx1 nCoV-19 and compared rates of severe COVID-19 outcomes (ie, COVID-19 hospital admission or death) across fortnightly periods, relative to 2-3 weeks after the second dose. Entry to the Scotland cohort started from May 19, 2021, and entry to the Brazil cohort started from Jan 18, 2021. Follow-up in both cohorts was until Oct 25, 2021. Poisson regression was used to estimate rate ratios (RRs) and vaccine effectiveness, with 95% CIs. FINDINGS: 1 972 454 adults received two doses of ChAdOx1 nCoV-19 in Scotland and 42 558 839 in Brazil, with longer follow-up in Scotland because two-dose vaccination began earlier in Scotland than in Brazil. In Scotland, RRs for severe COVID-19 increased to 2·01 (95% CI 1·54-2·62) at 10-11 weeks, 3·01 (2·26-3·99) at 14-15 weeks, and 5·43 (4·00-7·38) at 18-19 weeks after the second dose. The pattern of results was similar in Brazil, with RRs of 2·29 (2·01-2·61) at 10-11 weeks, 3·10 (2·63-3·64) at 14-15 weeks, and 4·71 (3·83-5·78) at 18-19 weeks after the second dose. In Scotland, vaccine effectiveness decreased from 83·7% (95% CI 79·7-87·0) at 2-3 weeks, to 75·9% (72·9-78·6) at 14-15 weeks, and 63·7% (59·6-67·4) at 18-19 weeks after the second dose. In Brazil, vaccine effectiveness decreased from 86·4% (85·4-87·3) at 2-3 weeks, to 59·7% (54·6-64·2) at 14-15 weeks, and 42·2% (32·4-50·6) at 18-19 weeks. INTERPRETATION: We found waning vaccine protection of ChAdOx1 nCoV-19 against COVID-19 hospital admissions and deaths in both Scotland and Brazil, this becoming evident within three months of the second vaccine dose. Consideration needs to be given to providing booster vaccine doses for people who have received ChAdOx1 nCoV-19. FUNDING: UK Research and Innovation (Medical Research Council), Scottish Government, Research and Innovation Industrial Strategy Challenge Fund, Health Data Research UK, Fiocruz, Fazer o Bem Faz Bem Programme; Conselho Nacional de Desenvolvimento Científico e Tecnológico, Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro. TRANSLATION: For the Portuguese translation of the abstract see Supplementary Materials section.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(21)02754-9

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Rate ratios for time since receiving two doses of ChAdOx1 nCoV-19 and severe COVID-19 (hospital admission or death) in Scotland and Brazil Analyses in Scotland were adjusted for age, sex, deprivation, comorbidities, number of previous tests, interval between doses, and temporal trend. Analyses in Brazil were adjusted for age, sex, deprivation, macroregion of residence, primary reason for vaccination, interval between doses, and temporal trend. Error bars are 95% CIs.
Figure 1 Rate ratios for time since receiving two doses of ChAdOx1 nCoV-19 and severe COVID-19 (hospital admission or death) in Scotland and Brazil Analyses in Scotland were adjusted for age, sex, deprivation, comorbidities, number of previous tests, interval between doses, and temporal trend. Analyses in Brazil were adjusted for age, sex, deprivation, macroregion of residence, primary reason for vaccination, interval between doses, and temporal trend. Error bars are 95% CIs.CC BY · PubMed Central
Figure 2 Rate ratios for time since receiving two doses of ChAdOx1 nCoV-19 and confirmed SARS-CoV-2 symptomatic infection in Scotland and Brazil Analyses in Scotland were adjusted for age, sex, deprivation, comorbidities, number of previous tests, interval between doses, and temporal trend. Analyses in Brazil were adjusted for age, sex, deprivation, macroregion of residence, primary reason for vaccination, interval between doses, and temporal trend. Error bars are 95% CIs.
Figure 2 Rate ratios for time since receiving two doses of ChAdOx1 nCoV-19 and confirmed SARS-CoV-2 symptomatic infection in Scotland and Brazil Analyses in Scotland were adjusted for age, sex, deprivation, comorbidities, number of previous tests, interval between doses, and temporal trend. Analyses in Brazil were adjusted for age, sex, deprivation, macroregion of residence, primary reason for vaccination, interval between doses, and temporal trend. Error bars are 95% CIs.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 32 references

Research works printed but not linked: 1

  1. Skowronski, 2021, Single-dose mRNA vaccine effectiveness against SARS-CoV-2, including alpha and gamma variants: a test-negative design in adults 70 years and older in British Columbia, Canada, Clin Infect Dis

Cited by

See all 141

Metadata

Authors
Katikireddi, S. V., Cerqueira-Silva, T., Vasileiou, E., Robertson, C., Amele, S., Pan, J., Taylor, B., Boaventura, V., Werneck, G. L., Flores-Ortiz, R., Agrawal, U., Docherty, A. B., McCowan, C., McMenamin, J., Moore, E., Ritchie, L. D., Rudan, I., Shah, S. A., Shi, T., Simpson, C. R., Barreto, M. L., Oliveira, V. D. A., Barral-Netto, M., & Sheikh, A.
Affiliations
  • MRC/CSO Social and Public Health Sciences Unit (GB)
  • University of Edinburgh (GB)
  • University of Strathclyde (GB)
  • Public Health Scotland (GB)
  • Universidade Federal da Bahia (BR)
  • Universidade do Estado do Rio de Janeiro (BR)
  • Instituto Gonçalo Moniz (BR)
  • University of St Andrews (GB)
  • University of Aberdeen (GB)
  • Victoria University of Wellington (NZ)
Corresponding author
Sheikh, Aziz
Venue
The Lancet
Publisher
Elsevier BV
Published
2022-01
Volume
399
Issue
10319
Pages
25-35
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W4200405047
Cited by
124
References
32
Citations by year
2026: 2 · 2025: 9 · 2024: 15 · 2023: 38 · 2022: 58
FWCI
8.94
Type
journal article
Language
en
Open access
Licence
Locations
  • The Lancet (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
  • Strathprints: The University of Strathclyde institutional repository (University of Strathclyde) (acceptedVersion)
  • Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, cc-by)
  • Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
  • Aberdeen University Research Archive (Aberdeen University) (submittedVersion)
  • St Andrews Research Repository (St Andrews Research Repository) (submittedVersion, cc-by)
  • LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
Funders
  • UK Research and Innovation (MC_PC_20058)
  • Medical Research Council (MC_PC_19075, MC_PC_19004)
  • Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro (E-26/210.180/2020)
  • Health Technology Assessment Programme (MC_UU_00022/2, 11/46/23, SCAF/15/02)
  • National Institute for Health Research
  • Conselho Nacional de Desenvolvimento Científico e Tecnológico
Topics
  • Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
  • Social Sciences › Health › Vaccine Coverage and Hesitancy
  • Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
Keywords
ChAdOx1 nCoV-19 vaccine, COVID-19 vaccine effectiveness, waning vaccine effectiveness, Delta variant, severe COVID-19 outcomes, COVID-19 hospitalization, COVID-19 mortality, vaccine protection duration, Scotland, Brazil
MeSH terms
COVID-19, SARS-CoV-2, COVID-19 Vaccines, Vaccine Efficacy, ChAdOx1 nCoV-19, Adolescent, Adult, Aged, Aged, 80 and over, Brazil, Female, Hospitalization, Humans, Immunization, Secondary, Male, Middle Aged, Retrospective Studies, Scotland, Time Factors, Vaccination

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Two-dose ChAdOx1 nCoV-19 vaccine protection against COVID-19 hospital admissions and deaths over time: a retrospective, population-based cohort study in Scotland and Brazil. https://app.cochat.ai/papers/10.1016/s0140-6736(21)02754-9
The paper
Katikireddi, S. V., Cerqueira-Silva, T., Vasileiou, E., Robertson, C., Amele, S., Pan, J., Taylor, B., Boaventura, V., Werneck, G. L., Flores-Ortiz, R., Agrawal, U., Docherty, A. B., McCowan, C., McMenamin, J., Moore, E., Ritchie, L. D., Rudan, I., Shah, S. A., Shi, T., . . . Sheikh, A. (2022). Two-dose ChAdOx1 nCoV-19 vaccine protection against COVID-19 hospital admissions and deaths over time: a retrospective, population-based cohort study in Scotland and Brazil. The Lancet. https://doi.org/10.1016/s0140-6736(21)02754-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.